| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/17/2013 | WO2013009843A1 Compositions against bacterial toxins |
| 01/17/2013 | WO2013009841A1 Subsets of antigen-presenting cells (apc's) in the human vagina and their distinct functions |
| 01/17/2013 | WO2013009826A1 Conjugating amines |
| 01/17/2013 | WO2013009564A1 Tyrosine ligation process |
| 01/17/2013 | WO2013009535A1 Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors |
| 01/17/2013 | WO2013009521A2 Methods and compositions for treating asthma using anti-il-13 antibodies |
| 01/17/2013 | WO2013009459A1 Urine assays, kits, and devices for typhoid fever diagnosis |
| 01/17/2013 | WO2013009210A1 Biological microchip for the estimation of immunoglobulin e and g levels in human blood, method of assay thereof, and reagent kit comprising same |
| 01/17/2013 | WO2013009165A1 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine |
| 01/17/2013 | WO2013008743A1 Chlamydophila pneumoniae antigen and usage thereof |
| 01/17/2013 | WO2013008185A1 Treatment with anti-pcsk9 antibodies |
| 01/17/2013 | WO2013008171A1 Antibodies that bind to ox40 and their uses |
| 01/17/2013 | WO2013008100A1 Methods for the treatment and prevention of thrombosis |
| 01/17/2013 | WO2013008099A1 Antibodies for the treatment and prevention of thrombosis |
| 01/17/2013 | WO2013008098A1 Antibodies for the treatment and prevention of thrombosis |
| 01/17/2013 | WO2013007956A1 Vaccine composition with aluminium hydroxide nanoparticles |
| 01/17/2013 | WO2013007772A1 Hbv polymerase mutants |
| 01/17/2013 | WO2013007770A1 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| 01/17/2013 | WO2013007678A1 Use of antagonists targeting metallothionein to treat intestinal inflammation |
| 01/17/2013 | WO2013007053A1 Fully human antibodies against human vegf |
| 01/17/2013 | WO2013007052A1 Fully human antibodies against human cd20 |
| 01/17/2013 | WO2012162243A3 Anti-cgrp compositions and use thereof |
| 01/17/2013 | WO2012158866A9 Treatment of autoimmune disorders and infections using antagonists of sgk1 activity |
| 01/17/2013 | WO2012158639A3 Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection |
| 01/17/2013 | WO2012151263A3 A synthetic hepatitis c genome and methods of making and use |
| 01/17/2013 | WO2012149454A3 Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use |
| 01/17/2013 | WO2012149406A3 Assessing and treating humans with long qt syndrome |
| 01/17/2013 | WO2012143382A3 Gpr177 as target and marker in tumors |
| 01/17/2013 | WO2012141989A3 Immunogens |
| 01/17/2013 | WO2012139097A3 Method of inducing neutralizing antibodies to human immunodeficiency virus |
| 01/17/2013 | WO2012112489A3 Compositions and methods for the therapy and diagnosis of influenza |
| 01/17/2013 | WO2012061558A3 Dual variable domain immunoglobulins and uses thereof |
| 01/17/2013 | US20130017600 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| 01/17/2013 | US20130017266 Radiation Therapy Agent |
| 01/17/2013 | US20130017253 Inducing Cellular Immune Responses to Human Papillomavirus Using Peptide and Nucleic Acid Compositions |
| 01/17/2013 | US20130017251 Antibody Specific for Apolipoprotein and Methods of Use Thereof |
| 01/17/2013 | US20130017224 Nucleic Acid Molecules Encoding Rantes, and Compositions Comprising and Methods of Using the Same |
| 01/17/2013 | US20130017222 Human prostate cell lines in cancer treatment |
| 01/17/2013 | US20130017221 Primers for detecting plasmodium |
| 01/17/2013 | US20130017220 Gel vaccine delivery system for treating poultry |
| 01/17/2013 | US20130017219 Purification of bacterial vesicles |
| 01/17/2013 | US20130017218 Live bacterial vaccine safety |
| 01/17/2013 | US20130017217 Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| 01/17/2013 | US20130017216 Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency |
| 01/17/2013 | US20130017215 Secreted campylobacter flagella coregulated proteins as immunogens |
| 01/17/2013 | US20130017214 Bacteremia-associated antigen from staphylococcus aureus |
| 01/17/2013 | US20130017213 Peptide analogues |
| 01/17/2013 | US20130017212 THERAPEUTIC USE OF THE ß2m PROTEIN |
| 01/17/2013 | US20130017211 Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| 01/17/2013 | US20130017210 Display of antibody fragments on virus-like particles of rna bacteriophages |
| 01/17/2013 | US20130017209 A-beta binding polypeptides |
| 01/17/2013 | US20130017208 Anti-IL-6 Antibodies, Compositions, Methods and Uses |
| 01/17/2013 | US20130017207 Chemotherapeutic methods and compositions |
| 01/17/2013 | US20130017206 Mcam modulation and uses thereof |
| 01/17/2013 | US20130017205 Inhibition of AXL Signaling in Anti-Metastatic Therapy |
| 01/17/2013 | US20130017204 Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae |
| 01/17/2013 | US20130017203 Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| 01/17/2013 | US20130017202 Pharmaceutical compositions and methods of treatment |
| 01/17/2013 | US20130017201 Bispecific monoclonal antibody capable of cross reacting with lethal factor (lf) and edema factor (ef), and neutralizing edema toxin (et) as well as lethal toxin (lt) of bacillus anthracis |
| 01/17/2013 | US20130017200 Multispecific antibodies, antibody analogs, compositions, and methods |
| 01/17/2013 | US20130017199 Simultaneous inhibition of pd-l1/pd-l2 |
| 01/17/2013 | US20130017198 Manipulation of calcium channels to regulate after-depolarization events in cardiac myocytes |
| 01/17/2013 | US20130017197 Stabilized antibody preparations and uses thereof |
| 01/17/2013 | US20130017196 Substituted imidazole derivatives |
| 01/17/2013 | US20130017195 Anti-folate receptor alpha antibodies and uses thereof |
| 01/17/2013 | US20130017194 Fak inhibitors |
| 01/17/2013 | US20130017193 Antibody formulations |
| 01/17/2013 | US20130017192 Diagnosis and Treatment of Autoantibody-Mediated Heart Disease |
| 01/17/2013 | US20130017191 Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| 01/17/2013 | US20130017190 Treatment of inflammatory diseases |
| 01/17/2013 | US20130017189 Functionalised Triblock Copolymers and Compositions Containing Such Polymers |
| 01/17/2013 | US20130017188 Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| 01/17/2013 | US20130017169 Multimeric forms of therapeutic proteins and uses thereof |
| 01/17/2013 | US20130017152 Method for the treatment of multiple sclerosis |
| 01/17/2013 | US20130017151 SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS |
| 01/17/2013 | CA2857369A1 Fully human antibodies against human cd20 |
| 01/17/2013 | CA2841970A1 Methods and compositions for treating asthma using anti-il-13 antibodies |
| 01/17/2013 | CA2841890A1 Hbv polymerase mutants |
| 01/17/2013 | CA2841534A1 Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| 01/17/2013 | CA2841356A1 Parenteral norovirus vaccine formulations |
| 01/17/2013 | CA2840482A1 Treatment with anti-pcsk9 antibodies |
| 01/17/2013 | CA2840460A1 Antibodies that bind to ox40 and their uses |
| 01/17/2013 | CA2840282A1 Use of antagonists targeting metallothionein to treat intestinal inflammation |
| 01/17/2013 | CA2838999A1 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| 01/17/2013 | CA2838817A1 Vaccine composition with aluminium hydroxide nanoparticles |
| 01/16/2013 | EP2546269A1 Monoclonal antibody against necrosis marker prdx4 and use thereof |
| 01/16/2013 | EP2546266A1 MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERp29 AND USE THEREOF |
| 01/16/2013 | EP2546260A1 Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
| 01/16/2013 | EP2545938A1 Therapeutic use of anti-tweak receptor antibodies |
| 01/16/2013 | EP2545937A1 Nanoemulsion vaccines |
| 01/16/2013 | EP2545936A2 Methods, compositions, and kits for treating Shiga toxin associated conditions |
| 01/16/2013 | EP2545382A2 Compositions and methods for screening for lyme disease |
| 01/16/2013 | EP2545174A2 Methods and compositions containing fc fusiong proteins for enhancing immune responses |
| 01/16/2013 | EP2545081A1 Free hexasaccharide isolated from several campylobacter species |
| 01/16/2013 | EP2545077A2 Monoclonal antibodies against c-met |
| 01/16/2013 | EP2545075A2 Humanized and chimeric anti-properdin antibodies |
| 01/16/2013 | EP2545074A2 Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| 01/16/2013 | EP2545067A1 Bluetongue virus recombinant vaccines and uses thereof |
| 01/16/2013 | EP2544768A1 Anti-cancer agent delivery vehicles capable of improved laoding |
| 01/16/2013 | EP2544721A1 Non-aqueous high concentration reduced viscosity suspension formulations |